Working… Menu
Trial record 1 of 1 for:    NCT00395031
Previous Study | Return to List | Next Study

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00395031
Recruitment Status : Completed
First Posted : November 2, 2006
Last Update Posted : July 29, 2011
Information provided by:
Manhattan Psychiatric Center

Brief Summary:
The aim of the protocol is to study the effects of 320 mg/day of ziprasidone (Geodon) on glucose and lipid metabolism of patients with both Diabetes Type II (DM) and schizophrenia or schizoaffective disorder, after switching their antipsychotic medication/s from typical and/or atypical to ziprasidone monotherapy.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorder Drug: Ziprasidone Phase 2 Phase 3

Detailed Description:

Inpatients with DSM IV diagnosis of schizophrenia or schizoaffective disorder and DM II will be enrolled after giving informed consent. Participants may stay on their original ward at MPC, if their clinical care would be better served on their home ward because of patient programs and/or continuity of care reasons. Patients recruited from other participating sites will be transferred to MPC research ward.

There will be a screening phase (two weeks) on the prior antipsychotic regimen, a cross-titration phase (three week) and a ziprasidone phase (eight weeks; four time points).

All medications, except for the antipsychotic agents, will be kept stable throughout the protocol. These medications may include anticholinergics, mood stabilizers and antidepressants. After the screening phase lasting two weeks, patients will enter the cross-titration phase lasting three week. The cross titration schedule will be changed in accordance with Deutschman & Deutschman's 2005 recommendations. The current antipsychotic will be gradually decreased to zero and ziprasidone will be started at 40 mg bid po and raised up to 160 mg po bid during the cross-titration phase, according to clinical response and tolerance. After the cross-titration phase has concluded, the ziprasidone dose will range from 80 mg bid p.o. to 160 mg bid p.o. daily according to clinical response during the eight week treatment phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder
Study Start Date : September 2003
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Arm Intervention/treatment
Open label
Drug: Ziprasidone
Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
Other Name: Geodon

Primary Outcome Measures :
  1. Reduced Glucose, Cholesterol and Lipid Levels [ Time Frame: 11 weeks ]

Secondary Outcome Measures :
  1. Reduction in dose requirement for antiglycemic agents [ Time Frame: 11 week ]
  2. Improvement in quality of life & Positive and Negative Symptoms [ Time Frame: 11 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Aged 18 to 65 years
  2. DSM IV diagnosis of schizophrenia (all subtypes) or schizoaffective disorder
  3. Diabetes Mellitus type II treated with oral antidiabetic drugs or insulin
  4. Stable dose of antipsychotic regimen for previous one month.
  5. Stable dose of antidepressant regimen for previous one month.
  6. Stable dose of adjunctive mood stabilizer and/or anticholinergic regimen for previous 1 month
  7. Signed informed consent
  8. Absence of significant cardiovascular pathology as demonstrated by EKG (QTc < 450 millisec)
  9. Absence of severe medical conditions (except for DM) requiring frequent changes in medication.

Exclusion Criteria:

  1. DSM IV diagnosis other than Schizophrenia or Schizoaffective disorder
  2. Unstable epilepsy
  3. Acute, unstable or significant medical condition
  4. Suicidal or physically violent behavioral episodes in the previous month
  5. Current DSM IV diagnosis of substance or alcohol abuse with positive urine toxicology in the past two weeks.
  6. Liver enzyme test values ≥ three times upper normal limit for AST, ALT, GGT, and Alkaline Phosphatase; ≥ two times upper limit for LDH.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00395031

Layout table for location information
United States, New York
Manhattan Psychiatric Center
New York, New York, United States, 10035
Sponsors and Collaborators
Manhattan Psychiatric Center
Layout table for investigator information
Study Chair: Saurabh Kaushik, M.D. Manhattan Psychiatric Center, New York University, Nathan Kline Institute
Principal Investigator: Jean-Pierre Lindenmayer, M.D. Manhattan Psychiatric Center, New York University, Nathan Kline Institute
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jean-Pierre Lindenmayer, Director of Psychopharmacology Research, Manhattan Psychiatric Center, NY, RFMH Identifier: NCT00395031    
Other Study ID Numbers: 03I/C24
Pfizer Reference # 2001-0448 ( Other Grant/Funding Number: Pfizer Inc )
First Posted: November 2, 2006    Key Record Dates
Last Update Posted: July 29, 2011
Last Verified: July 2011
Keywords provided by Manhattan Psychiatric Center:
Schizoaffective Disorder
metabolic markers
Additional relevant MeSH terms:
Layout table for MeSH terms
Psychotic Disorders
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents